<SEC-DOCUMENT>0000950170-23-002963.txt : 20230216
<SEC-HEADER>0000950170-23-002963.hdr.sgml : 20230216
<ACCEPTANCE-DATETIME>20230216073036
ACCESSION NUMBER:		0000950170-23-002963
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230215
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230216
DATE AS OF CHANGE:		20230216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inozyme Pharma, Inc.
		CENTRAL INDEX KEY:			0001693011
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				475129768
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39397
		FILM NUMBER:		23637135

	BUSINESS ADDRESS:	
		STREET 1:		321 SUMMER STREET
		STREET 2:		SUITE 400
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		857-330-4340

	MAIL ADDRESS:	
		STREET 1:		321 SUMMER STREET
		STREET 2:		SUITE 400
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Inozyme Pharma, LLC
		DATE OF NAME CHANGE:	20161222
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>inzy-20230215.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-02-15T21:50:15.2463+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:inzy="http://www.inozyme.com/20230215">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_bd5d4a7c-ba98-4a39-9001-45a25da63d56" name="dei:EntityCentralIndexKey" contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff">0001693011</ix:nonNumeric><ix:nonNumeric id="F_6d05de55-0583-4adf-a88c-1404e7cb6335" name="dei:AmendmentFlag" contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="inzy-20230215.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_12e50237-dda5-4cdc-a55b-62f60f108fff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001693011</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-15</xbrli:startDate><xbrli:endDate>2023-02-15</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <p style="border-top:2.25pt double rgba(0,0,0,1);text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_34f3a8c3-37bb-4fa7-b6a3-58b384fca4c3" contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_10af6b0f-d569-49ea-8d92-e31579b6354a" contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 15, 2023</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:24.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e8a65778-402f-41dd-ad05-2bae8225d686" contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:24.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INOZYME PHARMA, INC.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:41.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0c52853c-9d1f-4c9e-970a-4549e2ecefd0" contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c68b069d-fa20-4608-9e0d-740ee0d9229a" contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39397</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_aa815e7c-fd4b-49ce-a6e8-3003d1766374" contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38-4024528</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or Other Jurisdiction<br />of Incorporation)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(IRS Employer<br />Identification No.)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_125968e7-d82b-417e-b594-7b359d3c5ff2" contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">321 Summer Street</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b902680c-115d-46d1-a46b-a45a9f5ebaa3" contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Suite 400</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3f7ef3c8-bec3-4b49-a776-32514af9b174" contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boston</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e8fdfbb5-a103-48ba-806c-561ddcd43c13" contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8d2c54c9-42aa-4d01-9e43-7c065a8fdce7" contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">02210</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registrant&#x2019;s Telephone Number, Including Area Code:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5b7069a0-5ed0-4521-9a28-bd3fe6424050" contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">857</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c41eebcd-7113-43fb-856c-6a9511a29897" contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">330-4340</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9.0pt;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd4523ad-4e64-4f51-ac55-76a28bd6fac9" contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_381980a2-1067-4caa-b773-be6183afc30b" contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e9c9e12e-78e3-4e02-9b29-5b560395f357" contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5d725def-cdc7-4f37-a642-e3f873a1b3d3" contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:9.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading<br />Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ce630555-b754-4a2c-9516-cfb6e4940627" contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4abe0901-919f-4fbf-bd5e-31982a47ade8" contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INZY</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_81c920a3-cd3c-48b9-9d27-c9546b31e7c8" contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#x202f;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#x202f;240.12b-2 of this chapter).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company </span><span style="font-size:10.0pt;"><ix:nonNumeric id="F_8a35ad7e-49c2-4705-9c77-4fbb0419a243" contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10.0pt;"><ix:nonNumeric id="F_9fc15f3f-1c72-463d-b9d2-f7b1d709d99c" contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double rgba(0,0,0,1);text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inozyme Pharma, Inc.&#x2019;s (the &#x201c;Company&#x201d;) audited financial statements for the fiscal year ended December 31, 2022, are not yet available. On February 16, 2023, the Company disclosed in a press release that it expects to report cash, cash equivalents, and short-term investments of approximately $127.9 million as of December 31, 2022. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The estimated cash, cash equivalents and short-term investments amount is preliminary and unaudited, represents management&#x2019;s estimate as of the date of this report, is subject to completion of the Company&#x2019;s financial closing procedures for the fourth quarter and fiscal year ended December 31, 2022, and does not present all necessary information for a complete understanding of the Company&#x2019;s financial condition as of December 31, 2022, or the Company&#x2019;s results of operations for the year ended December 31, 2022. The actual financial results may differ materially from the preliminary estimated financial information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information in this Item 2.02, including Exhibit 99.1,  shall not be deemed &#x201c;filed&#x201d; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As previously disclosed, the Company is party to a Loan and Security Agreement (the &#x201c;Loan Agreement&#x201d;), dated July 25, 2022 (the &#x201c;Closing Date&#x201d;), with K2 HealthVentures LLC (&#x201c;K2HV&#x201d;, together with any other lender from time to time party thereto, the &#x201c;Lenders&#x201d;), K2HV, as administrative agent for the Lenders, and Ankura Trust Company, LLC, as collateral agent for the Lenders. The Loan Agreement provides for up to $70.0 million aggregate principal amount in term loans, subject to certain customary conditions. The Loan Agreement provided the Company access to a first tranche commitment of $25.0 million, of which $5.0 million was funded on the Closing Date and $20.0 million was available to be drawn at the Company&#x2019;s option through March 31, 2023 ( collectively, the &#x201c;First Tranche Commitment&#x201d;). On February 15, 2023, the Company elected to draw down the remaining $20.0 million of the First Tranche Commitment. Immediately following this $20.0 million drawdown, $45.0 million of borrowing capacity remained available under the Loan Agreement, subject to the terms and conditions set forth therein.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The foregoing description of the Loan Agreement is qualified in its entirety by reference to the full text of the Loan Agreement which was filed as Exhibit 10.1 to the Quarterly Report on Form 10-Q filed by the Company on August 15, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7.01 Regulation FD Disclosure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 16, 2023, the Company issued a press release announcing positive topline pharmacokinetic, pharmacodynamic, and safety data from its ongoing Phase 1/2 clinical trials of INZ-701 in adult patients with ENPP1 Deficiency and ABCC6 Deficiency. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information in this Item 7.01, including Exhibit 99.1, shall not be deemed &#x201c;filed&#x201d; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.01 Other Events.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Runway</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company expects that its cash, cash equivalents and short-term investments as of December 31, 2022, together with the additional $20.0 million borrowed on February 15, 2023 under the Loan Agreement, will enable the Company to fund its cash flow requirements into the fourth quarter of 2024. The Company has based this estimate on assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than it currently expects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 1/2 Clinical Trials of INZ-701 for ENPP1 Deficiency and ABCC6 Deficiency</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 16, 2023, the Company announced positive topline pharmacokinetic, pharmacodynamic, and safety data from its ongoing Phase 1/2 clinical trials of INZ-701 in adult patients with ENPP1 Deficiency and ABCC6 Deficiency. The Company also reported patient reported outcome data as measured by global impression of change (&#x201c;GIC&#x201d;) in the Phase 1/2 clinical trial of INZ-701 in adult patients with ENPP1 Deficiency.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Summary of Topline Data for Phase 1/2 Clinical Trial of INZ-701 for ENPP1 Deficiency</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ongoing Phase 1/2 open-label clinical trial initially enrolled nine adult patients with ENPP1 Deficiency at sites in North America and Europe. The trial will primarily assess the safety and tolerability of INZ-701 in adult patients with ENPP1 Deficiency, as well as characterize the pharmacokinetic and pharmacodynamic profile of INZ-701, including evaluation of plasma pyrophosphate (&#x201c;PPi&#x201d;) and other biomarker levels. In the Phase 1 dose-escalation portion of the trial, the Company assessed INZ-701 for 32-days at doses of 0.2 mg/kg (n=3), 0.6 mg/kg (n=3), and 1.8 mg/kg (n=3) administered via subcutaneous injection with three patients per dose cohort. Patients received a single dose and then began twice weekly dosing one week later. The Phase 1 dose-escalation portion of the trial seeks to identify a safe, tolerable dose that increases PPi levels, and that can be used for further clinical development. The open-label Phase 2 portion of the trial is assessing long-term safety, pharmacokinetics, and pharmacodynamics of continued treatment with INZ-701 for up to 48 weeks, where patients may receive doses of INZ-701 at home depending on site-specific protocols. Exploratory endpoints include evaluations of ectopic calcification, skeletal, vascular, and physical function, patient-reported outcomes, and exploratory biomarkers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pharmacodynamic Data </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(as of January 25, 2023)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The mean baseline PPi across all three cohorts was 426&#xb1;407 nM. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A rapid, significant, and sustained increase in PPi was observed in all patients, with a target PPi threshold observed from the lowest dose of 0.2 mg/kg.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PPi increased in all patients to levels comparable to those observed in the Company&#x2019;s study of healthy subjects (n=10), which study showed PPi levels between 1002 nM and 2169 nM.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table 1:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  PPi levels after INZ-701 administration in ENPP1 Deficiency.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:84.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10.847%;"></td>
    <td style="width:0.794%;"></td>
    <td style="width:13.988%;"></td>
    <td style="width:0.805%;"></td>
    <td style="width:15.498%;"></td>
    <td style="width:21.781%;"></td>
    <td style="width:8.907%;"></td>
    <td style="width:5.423%;"></td>
    <td style="width:8.907%;"></td>
    <td style="width:10.45%;"></td>
    <td style="width:2.601%;"></td>
   </tr>
   <tr style="height:14.25pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mean PPi (nM) &#xb1; SD</span></p></td>
    <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:39.75pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cohort 1 (0.2 mg/kg)*</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cohort 2 (0.6 mg/kg)</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cohort 3 (1.8 mg/kg)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:14.25pt;">
    <td rowspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 1</span></p></td>
    <td colspan="3" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Single Dose</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Day 1-8</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1229&#xb1;410</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1438&#xb1;715</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1220&#xb1;426</span></p></td>
   </tr>
   <tr style="height:14.25pt;">
    <td colspan="3" style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2x/Week Dose</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Day 11-32</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1494&#xb1;498</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1745&#xb1;780</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1341&#xb1;330</span></p></td>
   </tr>
   <tr style="height:14.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 2</span></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2x/Week Dose</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Day 32-338</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1299&#xb1;490</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1472&#xb1;516</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1462&#xb1;233</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*Cohort 1 &#x2013; n=2 post week 12</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pharmacokinetic Data </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(as of January 25, 2023)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INZ-701 activity in a dose proportional manner was observed.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long half-life of approximately 126 hours and drug accumulation as shown by a greater than dose proportional exposure suggests the potential for once weekly dosing.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Safety Data </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(as of January 10, 2023)</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INZ-701 was generally well-tolerated and exhibited a favorable safety profile, with no serious or severe adverse events attributed to INZ-701 and no adverse events leading to study withdrawal. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three of nine patients experienced mild adverse events related to INZ-701.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Injection site reactions (bruising or pain) occurred in two of nine patients.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other related adverse events included decreased appetite and fatigue.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were two serious adverse events not related to INZ-701.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All nine patients enrolled in the Phase 2 portion of the trial, one of whom subsequently withdrew from the trial following week 12 due to travel reasons. Eight patients continue on INZ-701 treatment.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Anti-Drug Antibody Data</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (as of January 25, 2023)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INZ-701 exhibited a favorable immunogenicity profile with low titers of non-neutralizing anti-drug antibodies (&#x201c;ADAs&#x201d;) observed in seven of nine patients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging Exploratory Clinical Data </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(as of January 27, 2023)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GIC is a patient reported outcome measure in the ongoing Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency. The measurement is performed by the clinician (&#x201c;C-GIC&#x201d;) and the patient (&#x201c;P-GIC&#x201d;), and assesses overall change in health from baseline on a 7-point scale as measured from &#x201c;very much worse&#x201d; (-3) to &#x201c;very much improved&#x201d; (+3). GIC is an exploratory endpoint and an early indicator of potential clinical outcomes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Six of eight patients showed concordant improvements on overall health on C-GIC and P-GIC.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Five of eight patients showed &#x201c;much improved&#x201d; (+2) or &#x201c;very much improved&#x201d; (+3) on P-GIC.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No patients showed a deterioration in overall health from baseline on C-GIC or P-GIC.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Anticipated Milestones</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company plans to initiate pivotal trial meetings with the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) in the first quarter of 2023.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company plans to initiate a Phase 1b clinical trial of INZ-701, or the ENERGY-1 trial, to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of INZ-701 in infants with ENPP1 Deficiency in the second quarter of 2023.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company plans to report interim clinical data from the ongoing Phase 1/2 clinical trial of INZ-701 in adults with ENPP1 Deficiency in the third quarter of 2023.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company plans to initiate a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency in the third quarter of 2023, subject to receipt of regulatory approval. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company plans to initiate protocol assistance meetings with the European Medicines Agency in the fourth quarter of 2023.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Summary of Topline Data for Phase 1/2 Clinical Trial in Adults with ABCC6 Deficiency</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ongoing Phase 1/2 open-label clinical trial initially enrolled nine adult patients with ABCC6 Deficiency at sites in the United States and Europe. The trial will primarily assess the safety and tolerability of INZ-701 in adult patients with ABCC6 Deficiency, as well as characterize the pharmacokinetic and pharmacodynamic profile of INZ-701, including the evaluation of levels of plasma PPi and other biomarkers. In the Phase 1 dose-escalation portion of the trial, the Company assessed INZ-701 for 32-days at doses of 0.2 mg/kg (n=3), 0.6 mg/kg (n=3), and 1.8 mg/kg (n=3) administered via subcutaneous injection with three patients per dose cohort. Patients received a single dose and then began twice weekly dosing one week later. The Phase 1 dose-escalation portion of the trial seeks to identify a safe, tolerable dose for further development that increases PPi levels. The open-label Phase 2 portion of the trial will assess long-term safety, pharmacokinetics, and pharmacodynamics of continued treatment with INZ-701 for up to 48 weeks, where patients may receive doses of INZ-701 at home depending on site-specific protocols. Exploratory endpoints include evaluations of ectopic calcification, vascular and retinal function, patient-reported outcomes and exploratory biomarkers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pharmacodynamic Data </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(as of January 10, 2023)</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The mean baseline PPi across all three cohorts was 947&#xb1;193 nM.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A rapid and significant increase in PPi was observed in all cohorts with a dose response observed.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PPi showed sustained increase in the highest dose cohort to levels comparable to those observed in the Company&#x2019;s study of healthy subjects (n=10), which study showed PPi levels between 1002 nM and 2169 nM.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table 2:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> PPi levels after INZ-701 administration in ABCC6 Deficiency.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:83.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10.263%;"></td>
    <td style="width:0.971%;"></td>
    <td style="width:16.745%;"></td>
    <td style="width:18.407%;"></td>
    <td style="width:11.245%;"></td>
    <td style="width:4.652%;"></td>
    <td style="width:11.245%;"></td>
    <td style="width:4.663%;"></td>
    <td style="width:12.416%;"></td>
    <td style="width:8.378%;"></td>
    <td style="width:1.015%;"></td>
   </tr>
   <tr style="height:14.25pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mean PPi (nM) &#xb1; SD</span></p></td>
   </tr>
   <tr style="height:39.75pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cohort 1 (0.2 mg/kg)</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cohort 2 (0.6 mg/kg)</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cohort 3 (1.8 mg/kg)</span></p></td>
   </tr>
   <tr style="height:14.25pt;">
    <td rowspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 1</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Single Dose</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Day 1-8</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1087&#xb1;796</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1326&#xb1;330</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1589&#xb1;1065</span></p></td>
    <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:14.25pt;">
    <td colspan="2" style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2x/Week Dose</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Day 11-32</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1023&#xb1;454</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1119&#xb1;216</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1415&#xb1;509</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:14.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 2</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2x/Week Dose</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Day 32-252</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">900&#xb1;253</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1011&#xb1;121</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1498&#xb1;465*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">* P&lt;0.05 vs 0.2 mg/kg &#x2013; Cohort 3 &#x2013; n=2 post day 18.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pharmacokinetic Data </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(as of January 10, 2023)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INZ-701 activity in a greater than dose proportional manner was observed.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long half-life of approximately 126 hours and drug accumulation as shown by a greater than dose proportional exposure suggests the potential for once weekly dosing.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Safety Data </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(as of January 16, 2023)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INZ-701 was generally well-tolerated and exhibited a favorable safety profile, with no serious or severe adverse events.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All adverse events were mild to moderate in severity.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Seven of nine patients experienced adverse events related to INZ-701.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Injection site reactions (discoloration, erythema, induration, pain, or pruritus) occurred in four of nine patients and were mild.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other related adverse events were erythema, fatigue, night sweats, pruritus, and urticaria.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">One patient from the highest dose cohort (1.8 mg/kg) was withdrawn from the Phase 1 portion of the trial at day 18 due to a moderate adverse event (erythema/urticaria) related to INZ-701.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Eight of nine patients enrolled in the Phase 2 portion of the trial and continue on INZ-701 treatment. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Anti-Drug Antibody Data </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(as of January 10, 2023)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INZ-701 exhibited a favorable immunogenicity profile with low titers of non-neutralizing ADAs observed in six of nine patients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Anticipated Milestones</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company plans to report interim clinical data from the ongoing Phase 1/2 clinical trial of INZ-701 in adults with ABCC6 Deficiency in the fourth quarter of 2023.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company plans to initiate a Phase 2/3 clinical trial of INZ-701 with ABCC6 Deficiency in 2024, subject to receipt of regulatory approval. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(d) Exhibits:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following exhibit is furnished herewith:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.843%;"></td>
    <td style="width:4.157%;"></td>
    <td style="width:85.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="inzy-ex99_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Press Release, dated February 16, 2023</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cautionary Note Regarding Forward-Looking Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements in this Current Report on Form 8-K about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute &#x201c;forward-looking statements&#x201d; within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the timing of planned clinical trials, the availability of data from clinical trials, the timing of planned regulatory meetings, the potential benefits of INZ-701 and the sufficiency of the Company&#x2019;s cash resources. The words &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;will,&#x201d; &#x201c;would&#x201d; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management&#x2019;s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company&#x2019;s ability to conduct its ongoing Phase 1/2 clinical trials of INZ-701 for ENPP1 Deficiency and ABCC6 Deficiency; obtain and maintain necessary approvals from the FDA and other regulatory authorities; continue to advance its product candidates in preclinical studies and clinical trials; replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; advance the development of its product candidates under the timelines it anticipates in planned and future clinical trials; obtain, maintain and protect intellectual property rights related to its product candidates; manage expenses; comply with the covenants under its outstanding loan agreement; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company&#x2019;s actual results to differ from those contained in the forward-looking statements, see the &#x201c;Risk Factors&#x201d; section in the Company&#x2019;s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties and other important factors, in the Company&#x2019;s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this Current Report on Form 8-K represent the Company&#x2019;s views as of the date hereof and should not be relied upon as representing the Company&#x2019;s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company&#x2019;s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6.0%;"></td>
    <td style="width:44.0%;"></td>
    <td style="width:4.0%;"></td>
    <td style="width:46.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INOZYME PHARMA, INC.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 16, 2023</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Axel Bolte</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name: Axel Bolte<br />Title: President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>inzy-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img4202433_0.jpg" alt="img4202433_0.jpg" style="width:178px;height:89px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Exhibit 99.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">- Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) observed and encouraging patient reported outcome data in all dose cohorts in ENPP1 Deficiency trial &#x2013;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">- Rapid and significant increase in PPi observed in all dose cohorts with sustained increase observed in highest dose cohort in ABCC6 Deficiency (PXE) trial -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">- INZ-701 was generally well-tolerated and exhibited a favorable safety profile in both trials -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">- Company updates its cash runway guidance to fund cash flow requirements into fourth quarter of 2024 &#x2013;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">- Company to host virtual investor and analyst event at 8:00 a.m. ET on February 16, 2023 -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">BOSTON, MA, February 16, 2023 - </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Inozyme Pharma, Inc.</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced positive topline pharmacokinetic (PK), pharmacodynamic (PD), and safety data from the ongoing Phase 1/2 clinical trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency (PXE). The Company also reported encouraging patient reported outcome data as measured by global impression of change (GIC) in the ENPP1 Deficiency trial.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x201c;We are pleased to share topline data today demonstrating that INZ-701 rapidly restored PPi to normal levels in all dose cohorts in the ENPP1 Deficiency trial, with normal PPi levels sustained during the trial. Additionally, emerging patient-reported outcome data, as measured by GIC, showed six of eight patients reported concordant improvements in overall health compared to baseline on clinician-GIC and patient-GIC,&#x201d; said Axel Bolte, MSc, MBA, Inozyme&#x2019;s co-founder, president and chief executive officer. &#x201c;In the ABCC6 Deficiency trial, we saw pharmacodynamic activity in all dose cohorts and we were particularly encouraged to see sustained PPi levels in the highest dose cohort.&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x201c;Data reported today are highly encouraging and show that INZ-701 significantly increased PPi levels into normal physiological ranges with a favorable safety profile,&#x201d; said Michael Levine, M.D., Professor Emeritus, Pediatrics and Medicine and Chief Emeritus, Division of Endocrinology and Diabetes at the Center for Bone Health at the Children&#x2019;s Hospital of Philadelphia Research Institute. &#x201c;The data presented today represent strong evidence to warrant continued clinical development of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Kurt Gunter, M.D., senior vice president and chief medical officer at Inozyme, added, &#x201c;People suffering from ENPP1 Deficiency and ABCC6 Deficiency are in desperate need of an effective therapeutic option. INZ-701 has shown in our ongoing clinical trials encouraging safety data, a predictable pharmacokinetic profile, and significant pharmacodynamic activity, all of which provide a strong foundation for advancing our trials. We are grateful to patients, families, and investigators for their continued support and participation in our research.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#x201c;We aim to achieve multiple key milestones in 2023, including the initiation of a pivotal trial of INZ-701 for pediatric patients with ENPP1 Deficiency,&#x201d; added Mr. Bolte. &#x201c;With our estimated cash position expected to fund cash flow requirements into the fourth quarter of 2024, we believe we are well positioned for success.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Phase 1/2 Clinical Trial in Adults with ENPP1 Deficiency</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Nine patients were initially enrolled in the ongoing Phase 1/2 clinical trial across three dose cohorts of INZ-701 (0.2 mg/kg (n=3), 0.6 mg/kg (n=3), and 1.8 mg/kg (n=3)). For trial design details, please see the section entitled &#x201c;INZ-701 in ENPP1 Deficiency Phase 1/2 Clinical Trial Design&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">below.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Pharmacodynamic Data </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(as of January 25, 2023)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Mean baseline PPi across all three cohorts was 426&plusmn;407 nM. </font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Rapid, significant, and sustained increase in PPi was observed in all patients, with a target PPi threshold observed from the lowest dose of 0.2 mg/kg.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">PPi increased in all patients to levels comparable to those observed in a study of healthy subjects (n=10), which showed PPi levels between 1002 nM and 2169 nM.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Table 1:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  PPi levels after INZ-701 administration in ENPP1 Deficiency.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:15.828%;"></td>
    <td style="width:14.936%;"></td>
    <td style="width:17.678%;"></td>
    <td style="width:22.558%;"></td>
    <td style="width:14.561%;"></td>
    <td style="width:14.44%;"></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Mean PPi (nM) &plusmn; SD</font></p></td>
   </tr>
   <tr style="height:39.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Cohort 1 (0.2 mg/kg)*</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Cohort 2 (0.6 mg/kg)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Cohort 3 (1.8 mg/kg)</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td rowspan="2" style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Phase 1</font></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Single Dose</font></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Day 1-8</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1229&plusmn;410</font></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1438&plusmn;715</font></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1220&plusmn;426</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2x/Week Dose</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Day 11-32</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1494&plusmn;498</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1745&plusmn;780</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1341&plusmn;330</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Phase 2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2x/Week Dose</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Day 32-338</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1299&plusmn;490</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1472&plusmn;516</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1462&plusmn;233</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">*Cohort 1 &#x2013; n=2 post week 12</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Pharmacokinetic Data </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(as of January 25, 2023)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">INZ-701 activity in a dose proportional manner was observed.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Long half-life of approximately 126 hours and drug accumulation as shown by a greater than dose proportional exposure suggests the potential for once weekly dosing.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Safety Data </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(as of January 10, 2023)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">INZ-701 was generally well-tolerated and exhibited a favorable safety profile, with no serious or severe adverse events attributed to INZ-701 and no adverse events leading to study withdrawal. </font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">3/9 patients experienced mild adverse events related to INZ-701.</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Injection site reactions (bruising or pain) occurred in 2/9 patients.</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other related adverse events included decreased appetite and fatigue.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">There were two serious adverse events not related to INZ-701.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">All nine patients enrolled in Phase 2, one of whom subsequently withdrew from the study following week 12 due to travel reasons. Eight patients continue on INZ-701 treatment.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Anti-Drug Antibody (ADA) Data </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(as of January 25, 2023)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">INZ-701 exhibited a favorable immunogenicity profile with low titers of non-neutralizing ADAs observed in 7/9 patients.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Emerging Exploratory Clinical Data </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(as of January 27, 2023)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">GIC is a patient reported outcome measure (PRO) in the ongoing Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency. The measurement is performed by the clinician (C-GIC) and the patient (P-GIC) and assesses overall change in health from baseline on a 7-point scale as measured from &#x201c;very much worse&#x201d; (-3) to &#x201c;very much improved&#x201d; (+3). GIC is an exploratory endpoint and an early indicator of potential clinical outcomes.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">6/8 patients showed concordant improvements on overall health on C-GIC and P-GIC.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">5/8 patients showed &#x201c;much improved&#x201d; (+2) or &#x201c;very much improved&#x201d; (+3) on P-GIC.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">No patients showed a deterioration in overall health from baseline on C-GIC or P-GIC.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Phase 1/2 Clinical Trial in Adults with ABCC6 Deficiency</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Nine patients were initially enrolled in the ongoing Phase 1/2 trial across three dose cohorts of INZ-701 (0.2 mg/kg (n=3), 0.6 mg/kg (n=3), and 1.8 mg/kg (n=3)). For trial design details, please see the section entitled &#x201c;INZ-701 in ABCC6 Deficiency Phase 1/2 Clinical Trial Design&#x201d; below.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Pharmacodynamic Data </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(as of January 10, 2023)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Mean baseline PPi across all three cohorts was 947&plusmn;193 nM.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Rapid and significant increase in PPi was observed in all cohorts with a dose response observed.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">PPi showed sustained increase in the highest dose cohort to levels comparable to those observed in a study of healthy subjects (n=10), which showed PPi levels between 1002 nM and 2169 nM.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Table 2:</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> PPi levels after INZ-701 administration in ABCC6 Deficiency.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:15.927%;"></td>
    <td style="width:17.898%;"></td>
    <td style="width:24.1%;"></td>
    <td style="width:13.515%;"></td>
    <td style="width:13.922%;"></td>
    <td style="width:14.638%;"></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Mean PPi (nM) &plusmn; SD</font></p></td>
   </tr>
   <tr style="height:39.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Cohort 1 (0.2 mg/kg)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Cohort 2 (0.6 mg/kg)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Cohort 3 (1.8 mg/kg)</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td rowspan="2" style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Phase 1</font></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Single Dose</font></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Day 1-8</font></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1087&plusmn;796</font></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1326&plusmn;330</font></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1589&plusmn;1065</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2x/Week Dose</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Day 11-32</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1023&plusmn;454</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1119&plusmn;216</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1415&plusmn;509</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Phase 2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">2x/Week Dose</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Day 32-252</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">900&plusmn;253</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1011&plusmn;121</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">1498&plusmn;465*</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">*P&lt;0.05 vs 0.2 mg/kg &#x2013; Cohort 3 &#x2013; n=2 post day 18.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Pharmacokinetic Data </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(as of January 10, 2023)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">INZ-701 activity in a greater than dose proportional manner was observed.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Long half-life of approximately 126 hours and drug accumulation as shown by a greater than dose proportional exposure suggests the potential for once weekly dosing.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Safety Data </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(as of January 16, 2023)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">INZ-701 was generally well-tolerated and exhibited a favorable safety profile, with no serious or severe adverse events.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">All adverse events were mild to moderate in severity.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">7/9 patients experienced adverse events related to INZ-701.</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Injection site reactions (discoloration, erythema, induration, pain, or pruritus) occurred in 4/9 patients and were mild.</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Other related adverse events were erythema, fatigue, night sweats, pruritus, and urticaria.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">One patient from the highest dose cohort was withdrawn from Phase 1 at day 18 due to a moderate adverse event (erythema/urticaria) related to INZ-701.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">8/9 patients enrolled in Phase 2 and continue on INZ-701 treatment. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Anti-Drug Antibody (ADA) Data </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(as of January 10, 2023)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">INZ-701 exhibited a favorable immunogenicity profile with low titers of non-neutralizing ADAs observed in 6/9 patients.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Anticipated Milestones</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">ENPP1 Deficiency </font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Start of FDA pivotal trial meetings&#x2014;Q1 2023</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Initiation of ENERGY-1 - Phase 1b clinical trial of INZ-701 to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of INZ-701 in infants&#x2014;Q2 2023</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Interim clinical data from ongoing Phase 1/2 trial in adults &#x2014;Q3 2023</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Initiation of pivotal trial in pediatric patients, subject to regulatory approval &#x2013; Q3 2023</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Start of EMA protocol assistance meetings &#x2013; Q4 2023</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">ABCC6 Deficiency </font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Interim clinical data from ongoing Phase 1/2 trial in adults&#x2014;Q4 2023</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Initiation of Phase 2/3 clinical trial, subject to regulatory approval - 2024</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Cash Runway Guidance</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company expects to report cash, cash equivalents, and short-term investments of approximately $127.9 million as of December 31, 2022. The estimated cash, cash equivalents, and short-term investments amount is preliminary and unaudited, represents management&#x2019;s estimate as of the date of this press release, is subject to completion of the Company&#x2019;s financial closing procedures for the fourth quarter and fiscal year ended December 31, 2022, and does not present all necessary information for a complete understanding of the Company&#x2019;s financial condition as of December 31, 2022, or the Company&#x2019;s results of operations for the year ended December 31, 2022. The actual financial results may differ materially from the preliminary estimated financial information.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Based on its current plans, the Company anticipates its cash, cash equivalents, and short-term investments as of December 31, 2022, together with the additional $20 million borrowed on February 15, 2023, under its existing debt facility, will enable the Company to fund cash flow requirements into the fourth quarter of 2024. This represents an increase of two quarters over the Company&#x2019;s previous guidance.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Investor and Analyst Event &#x2013; Webcast and Conference Call Details</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The Company will host an Investor and Analyst Event today, Thursday, February 16, 2023, at 8:00 a.m. ET to present the topline results from the trials in greater detail as well as provide an</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">overview of the opportunity and planned development milestones in each indication today. Joining the call will be members of the Inozyme management team as well as the following key opinion leaders:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4671798606054303%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Michael A. Levine, M.D., Professor Emeritus, Pediatrics and Medicine and Chief Emeritus, Division of Endocrinology and Diabetes at the Center for Bone Health at the Children&#x2019;s Hospital of Philadelphia Research Institute </font></div></div>
  <div style="margin-left:3.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4671798606054303%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Wilko Spiering, M.D., Ph.D., Associate Professor, Division of Internal Medicine and Dermatology, Department of Vascular Medicine, at the University Medical Center Utrecht of Utrecht University </font></div></div>
  <div style="margin-left:3.87%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:8.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4671798606054303%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Mark Kiel, M.D., Ph.D., Founder and Chief Science Officer of Genomenon</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The live webcast and replay will be accessible through the </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Investor Relations</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x202f;section of Inozyme&#x2019;s website under </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">News and Events</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">. Alternatively, the conference call may be accessed by dialing:<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Domestic Dial-in Number: 1-877-317-6789</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">International Dial-in Number: 1-412-317-6789</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Participants should ask to be joined into the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Inozyme Pharma</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> call.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">About ENPP1 Deficiency</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">ENPP1 Deficiency is a progressive condition that manifests as a spectrum of diseases. Individuals who present in utero or in infancy are typically diagnosed with generalized arterial calcification of infancy (GACI), which is characterized by extensive vascular calcification and intimal proliferation (overgrowth of smooth muscle cells inside blood vessels), resulting in myocardial infarction, stroke, or cardiac or multiorgan failure. Approximately 50% of infants with ENPP1 Deficiency die within six months of birth. Children with ENPP1 Deficiency typically experience rickets, a condition also known as autosomal-recessive hypophosphatemic rickets type 2 (ARHR2), while adults experience osteomalacia (softened bones), and they can exhibit a range of signs and symptoms that include hearing loss, arterial calcification, and cardiac and/or neurological involvement. There are no approved therapies for ENPP1 Deficiency.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">INZ-701 in ENPP1 Deficiency Phase 1/2 Clinical Trial Design</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The ongoing Phase 1/2 open-label clinical trial initially enrolled nine adult patients with ENPP1 Deficiency at sites in North America and Europe. The trial will primarily assess the safety and tolerability of INZ-701 in adult patients with ENPP1 Deficiency, as well as characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile of INZ-701, including evaluation of plasma pyrophosphate (PPi) and other biomarker levels. In the Phase 1 dose-escalation portion of the trial, Inozyme assessed INZ-701 for 32-days at doses of 0.2 mg/kg, 0.6 mg/kg, and 1.8 mg/kg administered via subcutaneous injection with three patients per dose cohort. Patients</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">received a single dose and then began twice weekly dosing one week later. Doses were selected based on preclinical studies and PK/PD modeling. The Phase 1 dose-escalation portion of the trial seeks to identify a safe, tolerable dose that increases PPi levels, and that can be used for further clinical development. The open-label Phase 2 portion of the trial is assessing long-term safety, pharmacokinetics, and pharmacodynamics of continued treatment with INZ-701 for up to 48 weeks, where patients may receive doses of INZ-701 at home depending on site-specific protocols. Exploratory endpoints will include evaluations of ectopic calcification, skeletal, vascular, and physical function, patient-reported outcomes, and exploratory biomarkers.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">About ABCC6 Deficiency</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">ABCC6 Deficiency is a rare, severe, inherited disorder caused by mutations in the ABCC6 gene, leading to low levels of PPi. PPi is essential for preventing harmful soft tissue calcification and regulating bone mineralization. ABCC6 Deficiency is a systemic and progressively debilitating condition, which affects more than 67,000 individuals worldwide. Infants with ABCC6 Deficiency are diagnosed with generalized arterial calcification of infancy (GACI) type 2, a condition that resembles GACI type 1, the infant form of ENPP1 Deficiency. In older individuals, ABCC6 Deficiency presents as pseudoxanthoma elasticum (PXE), which is characterized by pathological mineralization in blood vessels and soft tissues clinically affecting the skin, eyes, and vascular system. There are no approved therapies for ABCC6 Deficiency.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> <br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">INZ-701 in ABCC6 Deficiency Phase 1/2 Clinical Trial Design&#x202f;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">The ongoing Phase 1/2 open-label clinical trial initially enrolled nine adult patients with ABCC6 Deficiency at sites in the United States and Europe. The trial will primarily assess the safety and tolerability of INZ-701 in adult patients with ABCC6 Deficiency, as well as characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile of INZ-701, including the evaluation of levels of plasma PPi and other biomarkers. In the Phase 1 dose-escalation portion of the trial, Inozyme assessed INZ-701 for 32-days at doses of 0.2 mg/kg, 0.6 mg/kg, and 1.8 mg/kg administered via subcutaneous injection with three patients per dose cohort. Patients received a single dose and then began twice weekly dosing one week later. Doses were selected based on preclinical studies and PK/PD modeling. The Phase 1 dose-escalation portion of the trial seeks to identify a safe, tolerable dose for further development that increases PPi levels. The open-label Phase 2 portion of the trial will assess long-term safety, pharmacokinetics, and pharmacodynamics of continued treatment with INZ-701 for up to 48 weeks, where patients may receive doses of INZ-701 at home depending on site-specific protocols. Exploratory endpoints will include evaluations of ectopic calcification, vascular and retinal function, patient-reported outcomes and exploratory biomarkers.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">About INZ-701</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">INZ-701 is a clinical-stage enzyme therapy in development for the treatment of rare disorders of the vasculature, soft tissue, and skeleton. In preclinical studies, the experimental therapy has</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">shown potential to prevent pathologic mineralization and intimal proliferation (the overgrowth of smooth muscle cells inside blood vessels), which can drive morbidity and mortality in devastating genetic disorders such as ENPP1 Deficiency and ABCC6 Deficiency. INZ-701 is currently in Phase 1/2 clinical trials for the treatment of adult ENPP1 Deficiency and ABCC6 Deficiency.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">About Inozyme Pharma</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. We are developing INZ-701, an enzyme therapy, to address pathologic mineralization and intimal proliferation which can drive morbidity and mortality in these severe diseases. INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">For more information, please visit </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">www.inozyme.com</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> and follow us on </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">LinkedIn</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Twitter</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">, and </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Facebook</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Cautionary Note Regarding Forward-Looking Statements</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute &#34;forward-looking statements&#34; within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the timing of our planned clinical trials, the availability of data from clinical trials, timing of planned regulatory meetings, the potential benefits of INZ-701, and the sufficiency of the Company's cash resources. The words &#34;anticipate,&#34; &#34;believe,&#34; &#34;continue,&#34; &#34;could,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;may,&#34; &#34;plan,&#34; &#34;potential,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;should,&#34; &#34;target,&#34; &#34;will,&#34; &#34;would,&#34; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company's ability to conduct its ongoing Phase 1/2 clinical trials of INZ-701 for ENPP1 Deficiency and ABCC6 Deficiency; obtain and maintain necessary approvals from the FDA and other regulatory authorities; continue to advance its product candidates in preclinical studies and clinical trials; replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; advance the development of its product candidates under the timelines it anticipates in planned and future clinical trials; obtain, maintain, and protect intellectual property rights related to its product candidates; manage expenses; comply with the covenants under its outstanding loan agreement; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">contained in the forward-looking statements, see the &#34;Risk Factors&#34; section in the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors, in the Company's most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof and should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Contacts</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Investors:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Inozyme Pharma</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Stefan Riley, Director of IR and Corporate Communications</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(857) 330-8871<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">stefan.riley@inozyme.com</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Media:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">SmithSolve</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Matt Pera</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(973) 886-9150</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">matt.pera@smithsolve.com</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img4202433_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img4202433_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "? 3X# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M60-.JA?-1P=I('&[*MG&!TKT&L#PEX1T[P=I366G^9(9'\R:>4@O(V,<XP
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ML1*#PS ]01THH22FVQU5[NA>^&__ "1SQ?\ [UU_Z3)7C4O^H?\ W3_*O??
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M\1Z)'%&H1$6]B 4 8  STKP'_A6'C;_H7YO_  (A_P#BZ/\ A6'C;_H7YO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
:*** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>4
<FILENAME>inzy-20230215_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-15T21:50:15.1803+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="inzy-20230215.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10200.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>inzy-20230215_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-15T21:50:15.1977+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>inzy-20230215.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-15T21:50:15.1479+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.inozyme.com/20230215" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:inzy="http://www.inozyme.com/20230215" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="inzy-20230215_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="inzy-20230215_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139870819546064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 15, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 15,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INOZYME PHARMA, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001693011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-39397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">38-4024528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">321 Summer Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">330-4340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INZY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>inzy-20230215_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="inzy-20230215.xsd" xlink:type="simple"/>
    <context id="C_12e50237-dda5-4cdc-a55b-62f60f108fff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001693011</identifier>
        </entity>
        <period>
            <startDate>2023-02-15</startDate>
            <endDate>2023-02-15</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff"
      id="F_bd5d4a7c-ba98-4a39-9001-45a25da63d56">0001693011</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff"
      id="F_6d05de55-0583-4adf-a88c-1404e7cb6335">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff"
      id="F_34f3a8c3-37bb-4fa7-b6a3-58b384fca4c3">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff"
      id="F_10af6b0f-d569-49ea-8d92-e31579b6354a">2023-02-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff"
      id="F_e8a65778-402f-41dd-ad05-2bae8225d686">INOZYME PHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff"
      id="F_0c52853c-9d1f-4c9e-970a-4549e2ecefd0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff"
      id="F_c68b069d-fa20-4608-9e0d-740ee0d9229a">001-39397</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff"
      id="F_aa815e7c-fd4b-49ce-a6e8-3003d1766374">38-4024528</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff"
      id="F_125968e7-d82b-417e-b594-7b359d3c5ff2">321 Summer Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff"
      id="F_b902680c-115d-46d1-a46b-a45a9f5ebaa3">Suite 400</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff"
      id="F_3f7ef3c8-bec3-4b49-a776-32514af9b174">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff"
      id="F_e8fdfbb5-a103-48ba-806c-561ddcd43c13">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff"
      id="F_8d2c54c9-42aa-4d01-9e43-7c065a8fdce7">02210</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff"
      id="F_5b7069a0-5ed0-4521-9a28-bd3fe6424050">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff"
      id="F_c41eebcd-7113-43fb-856c-6a9511a29897">330-4340</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff"
      id="F_cd4523ad-4e64-4f51-ac55-76a28bd6fac9">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff"
      id="F_381980a2-1067-4caa-b773-be6183afc30b">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff"
      id="F_e9c9e12e-78e3-4e02-9b29-5b560395f357">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff"
      id="F_5d725def-cdc7-4f37-a642-e3f873a1b3d3">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff"
      id="F_ce630555-b754-4a2c-9516-cfb6e4940627">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff"
      id="F_4abe0901-919f-4fbf-bd5e-31982a47ade8">INZY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff"
      id="F_81c920a3-cd3c-48b9-9d27-c9546b31e7c8">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff"
      id="F_8a35ad7e-49c2-4705-9c77-4fbb0419a243">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_12e50237-dda5-4cdc-a55b-62f60f108fff"
      id="F_9fc15f3f-1c72-463d-b9d2-f7b1d709d99c">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
MT3M05C1_K72,!   TQ$  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6R-
MF&%SXC80AO^*QNUTVAD2;!D(28$9AR0]YBZ$!MJ;2Z<?A"U $]MR)3DD_[XK
M S:]FC5?P#;6RZ/5ZMVU!UNI7O6&<T/>DSC50V=C3';3;NMPPQ.F+V7&4_AE
M)57"#)RJ=5MGBK.H&)3$;>JZO7;"1.J,!L6UF1H-9&YBD?*9(CI/$J8^;GDL
MMT/'<PX7GL5Z8^R%]FB0L36?<_-'-E-PUBY5(I'P5 N9$L570R?P;FYISPXH
M[OA3\*T^.B9V*DLI7^W))!HZKB7B,0^-E6#P]<;'/(ZM$G#\LQ=URO^T X^/
M#^H/Q>1A,DNF^5C&7T5D-D.G[Y"(KU@>FV>Y_<3W$^I:O5#&NO@DV]V]G8Y#
MPEP;F>P' T$BTMTW>]\'XG@ /3& [@?0@GOW1P7E'3-L-%!R2Y2]&]3L03'5
M8C3 B=2NRMPH^%7 .#.ZDV$.038D2"-RGQIA/L@DW:TV1&W0-O G]M9VN!>\
MW0G2$X(/?'E)O&Z+4)?Z_QW>!K82D): M-#S3^B-Y1M7Y*]@J8V")?R[CFBG
MT*E7L'E]HS,6\J$#B:NY>N/.Z*<?O)[[*\+GEWP^IEX%</&1\3HX?'C_XC,"
MT2DA.JA*  110?$0LW4=!3Y^Q6+-$8YNR=$]+Q@SKH2T"1412,O:N.!*91HU
MY5&O1.NA@OO<?N9K83,)&*<LJ07#=2;3IY=OC_=D]BEX?@Q:9#(=7R)X5R7>
MU3EX8PB>8C%LP8B_D\_\HPX05W)=U^M=^Z[G(5C]$JM_#M9]PM5:I&OR&XPW
M&S*62<;26CA<SZ@<R[/K$NL:E9GS,%?""*Y)$$+2BYB3:9XLN:I#PK4@7!?^
MM7]]A7!Y;F6G[CD!FZ2A5)E4A8FVR-S )B!20>!R6&!89QG5YEZ#^MT]!GGD
M^=XYD OV3B819)Q8B; @18+8(.GW+SHN[71I'R.L3-]#/?M &$01.+9N'0[(
M%[B//*7UL<,E?>J1.?0>4$W@,M1+#+1R?P_W;Q1TL96UH+CD/!>0+!W7Q0"K
MRN#AUOX]X-B>028NY+:^NN-RMQ):DA0CJVJ%AUO\]V3E)IDI^2;2L'Z1<<W'
M $.K:H5W5K$HT68P:W#E%Y&=WKFXHDNIARYH52@\W-^+!0R@ S^-@@OTNZC5
M5:7!P[W\BPPA)K.-3#'S;1#Q??>BXW?0T%15P<.M_"O4!,-36YZ2/-U[FJZE
MPH6:^B%:U0.*._9<QB*$2@6U\Q'26PD6UW:PN$HC3V7]%/?IF>(7(82'P_[:
MM:W0.8(E/JU6]>O7H-=(=M3GX_[\/[*)UCF0-0+BLHV E=73LZS^_ITLH'_4
MHBB8NT:WE@M7:^2J')[BEKP0!MH?N2(>_7GY"]GW1K7-68.2W3<P)W#X\+5%
M,J;(&XMS3GYT+VU723)8![UA"N6N_)_B7@U1C.R^F'\D2UF_*W"!R?3E&T92
MV3W%S?D0,EC;<,/2-3_Y;- @- WF=\'O=4SMHT=T^[KCD=F&6I.8KT#)O;R"
MJ:K=&X3=B9%9\=2^E,;(I#C<< 8[P=X OZ^D-(<3^R*@?(\S^A=02P,$%
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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MX_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0
M   ( -$[4%8'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ T3M05KHII13M    *P(  !$
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M;',O+G)E;'-02P$"% ,4    " #1.U!6.JJBYT !   \ @  #P
M    @ &3$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ T3M05B0>FZ*M
M    ^ $  !H              ( ! !(  'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ T3M05F60>9(9 0  SP,  !,
M ( !Y1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  +Q0
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="inzy-20230215.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="inzy-20230215.htm">inzy-20230215.htm</File>
    <File>inzy-20230215.xsd</File>
    <File>inzy-20230215_lab.xml</File>
    <File>inzy-20230215_pre.xml</File>
    <File>inzy-ex99_1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "inzy-20230215.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 24
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "inzy-20230215.htm"
     ]
    },
    "labelLink": {
     "local": [
      "inzy-20230215_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "inzy-20230215_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "inzy-20230215.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "inzy",
   "nsuri": "http://www.inozyme.com/20230215",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "inzy-20230215.htm",
      "contextRef": "C_12e50237-dda5-4cdc-a55b-62f60f108fff",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "inzy-20230215.htm",
      "contextRef": "C_12e50237-dda5-4cdc-a55b-62f60f108fff",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inozyme.com/20230215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950170-23-002963-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-002963-xbrl.zip
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M\5_"?B_XE$8XYXZ@OVP$+33@?&/H<\JR7*X'"%5<J[OA>'4@FI$?#+/?=0D
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M 3.8SZ7J<$Q1T.#]B?K:&/#_,$W&%4NO$6*.8O-N&KNC%#G%X%Z1P37I$'0
MP51JDP/=2%4RMZ:BT2$8I(+T#/3M 4MBP+:"6NL+><2"2N<3U#0I0-G(F""T
MVL$S>*27OH-T3<>2$!?4RV;K6L<4U)[@Z<0U!WVIP1;QTXA3<3N"LY*A@KZ7
MR1EU8#EIN3#>7->"LM34DH0&"2IEF>7@S@O1Y5G&W0M9;+^XE&7_5P?#Z-@D
MQ\Y 347E$),N@!H,.PW<&B:8@?**Y3$79YH5_@CXK)SLR[ 59:,OV.@6.4Y9
MG>:"DA.>(NK-S?,OC3P8*$^;#ZHT&)CQ6/N)1A3!=CEB -BC-$7HBUMCHN-Y
M)L86BX<-Y(A'0E>;<IG(I+84%PU(5.A (9HA2Z'DMX3&0N&I#NW)T3!E$E8+
M-"X:UN\:-!X(OO(_!8QH.E*[6+*B2PWM!!HVOA->]U]-\@NC43[Z7^A4*&^_
M_7:,YYKRTU_-7_ZW^@16D0SEL6WML!=\DD3BNF>IGL"^"6:)?\MUHH&8)W(7
MZN6(;[+&?' LR>("V%^!GR*#-RBU<5XK5>5W4DD\BK\5*257:9'EU?YV< 6B
M'W%_#90G/#]8U8?4P1;WM3I4D%I<,<&E_- '))E;W4-H.T0E>E*G&Z]4=1"
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M 4K9]\0CW'4ZON@6%MG  ^F) DU^T2\FG5_2Y7C+>W>/T^L:OB<LEI['QK)
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M!C'O*;Q0>%'BA45VZSCVN_%B7;BP:&$93S'86Z8*;(^MM<(EGB;7M]A&*UU
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M^CJ\\HD'A30HHH=H-!_Q5)%H:]%%D6AK2+0ADQ?UY$6BF[  6J7<GSO+GDZ
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M_HC&0S&!,1>[OZ!TSH$B:&BNZ0C(=);XY[U0><Q*8;*H5CUENEVP/FO\ZSP
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M%$W21G]%0^:V4)]2-%:E)!ICB<4:>ZUMG10<=&EJ(Y*D*]TE]IU'[B9X/>W
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MS' #=KVT9-T,I$X)$)'('-X$9HUG4#$PGT2GZ!U0&CXR-P;],:7;+$A4@Q=
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M@#^.RP0T-A^J(6<YSM.BAHN20]$!M+CRXS_@$[J7*J_H90\YU3>+_;!M2 ,
M0:YGK1#A"'Q[??GVLVH0"U8RQ3FV@:SW.(F*_^:*DK&Z1SX9:W]]$><KDU L
MIXO'J9LXR;->J]?K_?7\#GAB:=.$S\^&B;B]"YK?,C#!AO/BG707)E49=TX
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M.9ED2H^$DI&L?-?>=0U"@Z%=8PA9E59-)3*0&8G\ X4)D.1BU\23E7Z"M=O
M@,J;*19>3@2N<,1>WJ8P,>XTL,Y+4/SP?,SVRH:3(!MVFJ">$]=^>'W))%CF
M!=L&4P!SD("=Z\Q%>B+8!&P#S$/:NW[WRSXR>30KM!II),2\ZO!!ET4%&3J#
MZ4F OX786=4*D'T8ER.C+8%S2(49PDKAU8,YO<0/*;EB>Y=-F.@^N=<H#2J?
M[-YU=9U;*_#_F9Y2V)9%8ZY&U.#7=PKU1E'94AL3LMA),X5UP.[!S 4F:.5S
MRKOY^H-&$9[!F[-)%HW93!LK_.7XG.TU>_MH1MV]3TY D()4K&[]/[W]%BO
MK3! 5;(PH6(_#5H'_,9-@DF9,0#489[7L);X50(ZWZ @:#<A8V6=8Q+!9;0V
M('\ZXA\?G%;^FKSG,?P::1-SY*N>#TWH9V!Y!7/,62)<(=9*G(>8Z0:X7P,M
M!5IZ%EHZ6D%+A6B_3ZIW]S%D_I$* -);H+) 93M-96_U'2+C+!8.@X15]_ E
M075'=_=B"TCO07I:(UUXLUPME6%7^E<^D&$'6W,19PGL'7D(+[Z_O#RN67;!
M%@D^BL_.,!8BHI15 "B)QG R7PB0KO9,>(<$CXRV>(C*".&/6T543L367155
M?SZVI[[K[3=8V:&MN("*<MFHRU\$N_X5,"+_GEA8@#OR,RX3VV!I@BE"((*$
MC\?F^7=HS+NDIE_4O"7+-,7N)<8K>EFI8@Q$HF?!';"C)/C\%4_BN8*!MK?B
MR1:< 0M%/D*1CU#DX[$B'QNT>[OC(@]9E<'A\"R(_T9P5?D.KJ]E80R@?\$;
M!(4M@.<^^X<G16''3K_'U)L-<-8%V@FT\RRT\XZGTI]X1DM3@DE*427E3[Y0
M5C+04[U"$!43PO![05+H)LJK"QEA4ZW@0R@G%$AKUTD+"2?W?UN %H<EQ0N4
MA?ZB,4Q#6%?W6&'"22*F(L'\_$G*?1HG)O./=8VT?%$OG_\/-J[WH\_QO ">
M ;7HNNJT]QL,8!"-BXG@G/*Q!\+-A%!@%+>[( 2)!W0[Q_T'!&)0J]?0P-@L
M5],'0N;NV39XE^K41 9Q5=@CAF>D=56X:]GG&[RX]Y&6\Y56<I3P9?!Q,E*-
M0'#1KTT0$CH#H2-O17SN1^Z?(+#R^P%5$IY:<68%\D\GO(^BW@9K*JT<R$2Z
M^5EQ]_G=9EA^[,Y1J]\EX;6R04!^TTGKM'_ZR$W=PU;GL7%ZK:/.T>,W];O=
MQVXZ;!WW%F>T,0W!-J*_SU>DE/7I5!%V*NS4-NX4[ O,0GWW3>^;)6FT%DWF
M0X.8KZK'DL\1];\]]6:?%?Y$]O[JB6TX>_W6<9"ZF\DAPDZ%G0H[%7;JB^[4
M9HG)LJ57E7FW'_9^I_:^BWM_'/9^%_>^Q_;*7-J5>_\D?Y31,V^1==?+(IO(
M.$Y$0*-G.Z7P*-=8!RP(S.39.E, /!/Q<5WJ R9L,R9@B_I.\S1@P09@P;,V
M9VZ?ECE\)_W'.W@'?-AR?.AUCPM\Z/7: 1]V'1^.3OMECF_[^.B338\'$8?1
MRKM'1XWB/P J@"#@TW9H'=W;@U^QK.Y'*:!AS[=BSTG3[#1[W;#AZ[3ASZM4
M=GN%T#@\.@P;OS,;W^F4VD*W\[@U$39^6S;^L'-4;/Q1N__9M,1-R ?: =1Y
M;K_T>NH& 1&":1"PX:L9#;UNLWL4.,.&X,)S:A?]=KO4*H]Z 2,"1G3:G4[I
MENP^'M8.*+']*''8/RV=#L='?WO(!H&_>/IMW<X+;AK(_W;];>+.86E';&I9
M51'0E]GKG;,R>:F\HK[KLE3C,6UT"YZ&PYOA7/0SE>"[D4JX4()OATEHC4JC
MA!+AH33*LR!^62<A<G**7>FHELD(.X\*P]R8*U\0)34:NQ5)K7C" +8*?JW7
M(MJ \D*!A@(-/0L-_:S5B(UY,FPF<DC]@GD*]'(K)T!$"4C:[C$;Z\Q8JNP3
M8[-5'D79)$M\41+NJ_,K[,;U*.V)6U!_L4N8S48C89WU;;K*IE5#[&*E(D']
MA^'E, *8BEM<1^A/D$A0F3]S6C@?"A =6ZLI'P=->6,TY7:0\D'*/Z>FC%KO
M2"CJF3,'*9LD@+N)P-I6OGSGZN;/UO/(O.ESPQ?K5)HV66<6^^M8,<6.&SR&
M/R#VX=M"<^>U5:P#R062>Q:2NTB2)6KP/6E@T!C+<$YT3'2'1BL1#QBP&T O
MP1 -]/(L]')RT*^Z-X&A"#<+, 7C92(R(B%I!2242[4G4DV':"00S2-]/YZ/
M:#Z-1D[:O?K_CI%(]-93QVOU6]X2S,(L@ @X?;-L#]9)LR5W3(,),W=C,>$-
M; R>%5=3+N%?4--2DX&@R>P^TU&4&>,+0!_6:0_5P%)2!=H*M+7MM/4+$(PI
MY<HJG:TBJB%0R2@#$TCAM)B=">ZP?5].5K[Q7T89,4;R#=#G@OT3]+GGH:JJ
M&Z=ORWM?GP+T2:!#(39\IORM><$6QHM4&19GU+N 5V;3 IVRO8)$#TKBV_]T
M53$09"#(K2'(TP4#J]8/-S^&0J(+;Y<JH][9A=/085!O H^UV.9'XD+GR]#Y
M,G2^#)TO-Q"/-RNN?@&"I'F%^2+X::#C.=N[N+K8W]Y(>\A)W6U:^A(!W-7Q
M63F99$J/A)*1K.*T/DR;Z!ES\(0A9%5:-97(G($9_"$5$.?5Q6)3QN.:FAA.
M*.PH*C^O6(AD2G;Y&T!2Z[02=GVA&Y*3@F,B.":>D2&\?'M]W:FU-+S/Q[ ^
M$:= ",]("+L9@GJ/<$#][-75!4OE5#N>,&<P)WXBA -%S?I3I(?G_^B0E1&H
M)%#)KE'):R6=],=.@%1>OGWY[H=_-3NL6<2+!BR"96(Q@IQVX*[2B:V9F/(D
MP] 11J)\2FN#^?17W\*UP=+%\[-Y/+>X&L\5+""R]7$E]N4=<C"62@+M!@(-
M!+JC!.K@]TE%AC'Z^BBDJ]5(H[\A)]6#;DZB>&0SSA)G64D_O4 _@7YVE'[J
M FY1#P1"244,OQH9E0XZ&#4;8&8@RC<C1G@J4YNY/\,)XJZJ/1*H*E#5CE)5
M:5R]?'.!OG&G88J,6RL!0GC:N#"Q:M1R^!"U!/=D<$_N%N/87??DQ?>7E\?!
M/1D(89<EZ*?8=:59]Z!(#>03R&>+R:=NUN7IM@>])6_EH[9<$PGH,.BD(37C
M>:!YR>V8O<O4C,_9#YF,T39:7]@&+-M4=OAA+-BEGJ1<S>F@=X1UP)#E8:$P
M%@$6-NA?)G[/)# ^[^C"0(S% T--T$4FH%],A:53"?9NT;+_Z'1/6GT\P)KD
M-<K@EBL1B<E &-;K4*)FM\5P)C */1;_F3?S"8#=,6D90#&1L&+,!*4S@(IG
M,2;J-7!A1EBZ'W:8CP0^Z]6B_KDM)Y!/$X-3,7ZESWYD2\?>!<B-!KZK)B<B
M@&,B"M'B*LA6XP]A4BI"G2Q*J)X:^D B$6<P+E5<PZ>&.C-NS'[/0&(#B' %
M0VE1-LT%-TP ?L=W(>AA$VL82&G'\F4RGB1,P;W6(C2D&B(RT1SQ=;R8M  @
MQ<*@$P8K@G_, C3<Z1[84CKCO'(0F!I%&> IG0I_+KI:_D.+]&C"(Y=AA;IR
M+L6 $^"6L1P.X0G<193D@('EB;<Z7E2H5@U3@TYK55+TVE$O6U]&&$3"IHJ$
M[X&UQ7CF3 )%45T"6 M8  K8;XV<@=T4V:/6W_HG6/9]G,/ID:"3X)0VC6_%
M3@5YY<K_Z+9+<3+0QNB9G^\K,3 ^^__(9_\W/%.CV8E;:=&QS&(Q<&S(HSS+
M8 8# ;>AU.WZZH"?#S/E!1$;8N*VP549X6<N%=RP@EG#<M P0#XE;5W:<,Q-
MB S*#6*N,UT\ S"8BGLX)3P^I:I>HUP'#%G@.TKQSV=JO":"U%[1N  "FUO'
M7M))[C(&\ZL8 "$XNN52*Q"P6 ^(7:)V<24<ETE(&]]1Q/Q2U@DQZK$F)&0/
MX*S3,0>^_F&<&4N?*K%P7(@%[MCI6;O->&O28B\_(+,O]&5DPP!_='65:F6I
M0))O")E_65PY)N1'088%'/$O.HAD# )+!15RH\\*;PXDPO'Q<'Q\$XZ/;YKX
M0;U\*F'%N3=$I^@5RQ2>ZZ1<Y 3[5\0@!*8BT2E:!FB8Y.?H4$P('HVQ^)N,
MO,^%A%.+_;>6"FT1'#1"'8J$VP"S7] 0*GU/KY7^8SX1-5<5<X)/ZN+&VR )
M&"@XX(V8PRQA<'A7(CAZ=,XVEYJ_5L+,Z4FHF[<]<<[#XY/.2?_TN'W</CKL
MM7MKES#SG"SLC8S&7"3LHL5^%E-84(.]:5VU&NS:Z*&P%E3HEQ.1U\N[+G):
M?>')-_ U0CV8K+ZQ%,/:O5=R*FUQ^D/%.C)2P>)'GC->23X0Z!CB7J.^%)BU
M0"[>[X$WLA\%3]RX_'4LDQ@LRLKO\:.VJ73^U,@U_ J<+$G'DK-WH*5S TSU
MM8+-=YD33TP""M0=J'MKJ/M7F=QH]CZ5<)<:E:0]IC\70-V1Q.A52>N+9$N9
M1.A072#T*X$A$")EN%VD '!2/."!_\MME"7<E \T"@K^'R6Q B J1O0;#)J3
M_/\X(Z(Q/5Y\K-T<:#?0[H[2[AMN;MA/4B1+9/M*^Z!%)73?4[:K8+\,AS+R
M,88?A-) E5JM?P;2INT+^AP38%!@854^;R,0\THSC4<84)<^9@1K&_D85=WA
M]R0@?.6,N-R7^D[X/G*5*__)"UF[W?3L9'AN\XKM)/;(J*Z43=AH*N3NZ6XS
M-Q%(U"OMY 3?IAULL8N$]!0'1)G,?0PZJF)0Y#_!Q(^2+D6,#1#!E $Q,3I[
M,3!; 8=PYF>7-:4U/_/SG(A_!9J.I0;J0-$ >O8V0R?I&>LT3T].FKW.2?/X
MY+0?JHD'"ME1"LD-^3P]ZBZ9'':Z@4P"F>PZF5QSXS,6,1_/CG66Q(S;&\S^
M -WQ-RT555W-$_N^E,[XG(E=/GIX3263MD$')F5_BUN0;U_"QF91S,5 9XXM
M5\%<7^@&/-M43G:GTJJTC&/NX A/&*'[L3I?X\;<80J('((=1$GSG%D\JF6R
M"3JT0$IC6KEML=?PR%3&&28ISL954B-H@QFHB!I/Y!1%\N"=W CFYBF&:Q)R
MF(R41N\))=WGK:EAW2 EC3],@_PWDL,BFP7>70RU]\/%Y>O]!KQ58L:+91$(
M'1[A8W]X?PSLGU"TLFD11EH<#;U7('TEP!P!D<!R_=$@MH>).+"[,Y@6O--.
MM(9/D\Q&"<!)))22:3'I<I!H';,I.H$2N]_(,S@Q,P:6/9GKB)LX/^G#3>3[
M,5IG](V@TTK^YP@_3O Y;49<L2&7269$BUTL'&P[:O^UA(#S;;/NL X JB_]
MCHV%Y2V;  *,*;UG((T;M\K0]SV/5[M3=6%E1D8W@DY6U ]A)5:S&Z5G=!Z+
M9TY;H*6D:>CL%X)]/$]U.M8V!702$["G\W'P)=AR:._BW8_ONGX/$U%4@JN]
M5ULG<$P>2<[VK!["AN+>8K+3OC_G 8K3'*"HBMKX,$7#U8B./%B@7>^CM/-)
M"I1M/69+%249[-U8<(QBLD1;7-M*E/-O*;8)/A_ 5BF1&8Q74MA1JJE.IL*W
M2/HPIC[H\)_2^=EM09,$4I?YB;MEF(<3%CO*[I]1$:_JD]ZA\*I6QV51@> #
MX?V50(+Y;#GDS[>ZE9;2V@G<-<YS7S]8[2+Y/W=,^6YQ'IT*U4SX0"3+M9(E
M%2DAL5_T!E24GX,RN6H<N%IG )&*X4S*/WZK\7#B!6;M1=S'!T%6IL*?H_8O
MHZ!V:D"M,;!&K,6'9]RKNLQ>L-=*,R^57/Z8237J*<MUU="?RUZL],SVKG_:
M7U7L&7ZXVB\[ZE2S:.0Z!((W+RQ=E.U,N)V 7CTWE>H#HUQ+/[ZF,Z8#"7AH
M;N!3@HG<I$?3O(K6I]@AM2GP!+X?&+/ :Z?\\XHQA;O% Q"VK( 1:AF];C/F
M<\J'Q-%(!6RWNFPR.K@9->#C<?$1Y]5IG?JO %S *0F*%W8'GX+>9;-!E#FN
M!)X*E64G\OR<K!&BVHD4SR=5S5U;[#K_)3#LC3Z%LCF0" >3PL&D<##I\_-&
M-.KEE!K/81$9$(;$YW,+7+&!0+^%F\D(T]C$#7IW?+D93+['*PR[<9L6NR)A
M-$,SV8H$A D:]$4!"%A7J9A8!_)5>/O]^J>#ZROJ_HT9-EZ7>(JLA%>)&ZHS
M)''3Y7"."P%EHVP!4:RH<!!0W03+0'#G,KIP-W!'[H:!8!E.&D7M$ LR@.BK
M"B16Q[/\7&N*5]%O>>4TT2='PMR[)=3(5[ HVE5\?(.*HI-S7/5O]A*[KB)D
M*4+D\)3VQZ(;!G>EE.:8XI3O>Z5"%,\#&,8:=(]8P-)\ 1]%6F 3'87H/BF+
M+8-Z\_(V!83V%>W@]A3T4E+<DJ1TQE1J%+T'$$.G,,B2,\;> ,XX5'X*GUX!
M@[DET \SE7O9\G4T?64IQ*_,19C9X9\0M2F5^I@-57B"QR@8V5LD%)\[=+=<
M(3KPCT UFT\USPG0.S75*1!IN!&8OC05^%>J,1[[Q)/NTFJ#6?(1S_(\ZTGF
M<CU!>J^)'Q'#APTZ@TX'W37U/O:Z&QWJO)8M4N<D%EW$("4J7*@&8<DK_ I/
MH28US$!=U$/'G+0V$RMBAGEY7GP 0U$,5NH#E[Z0WQV>X%=HY]9'P4A?J>*N
MJ"H+\G/Y(<L(6Q';Y,,A5<F<:$/ZJ6+')XUVNTW'_,O@JS9)#. 6Z$NJQ0?O
MS 5C4Y\A\)K'\!9#@J0=8P1X OJT97BCOZ_CD^A]Y!*!/O$]W)8"8>@& WZ-
M!=2JI37NKJ&J<699:D46ZUL8%_11SD3",74WF["]ZW^^?# ^# KBN(SB+>XA
M8M9"9-='$2NLL*6RCPY,VJ"BO((%[;S!Q+Q0-,O@LT> CXL1+B\YZ*4[QB79
MESQ%\D4"D7>H^)% 9'&0*F!^T*@"K_A:P;Z[^D,MV)<?Q$<][;VCLJQ?+N"W
M/+$O%_##\1:#?I66F8?_4,]<$>[;_D ?VQE'<=WQ6R_'=:\#^6F>8"*9G%""
M(_BN([C4JKU!!FO\..=O\/T&36-](+99RKSW>.:$O[Y #2&(355D2Y4/_66%
M?,<SA2,0"XI4(.\FP;XB"U*W:.51"3D0'<;[NKP#L2QQF4L.EY'#L7+IY'T#
M*,"(7KS7*[4,[\CR.>KX'E2J\RF!. \29*.36C8'$B'/*>0YA3RGS\\;[1C/
M,Z7:Y?$A7Z>?ROQ7X8+E8,$#Y\BHB/.?/4OF0Q>8;10;M+TFV@QD7-2"AF\@
M??";EX7<Y@$D#.>@CZ.2?#;#,))=D;F-S0R60PVL)H;S;CP)O:3R+2TZE.QJ
M\>N]-A_WSLWE/T&;7&MC965%@O6#;<"R3948BQB&OMJHQ?;><AOSW\^0E?YK
M?Z4]4Q@GU)]K('7NO!.9(\8:Y4UH<B,'^;H"05)8&W3;/7RW.)W-) Q1Q:4_
MUN[YU<>F:R\N?>!XS';!#$.O*#9*HR:5?T9 /D'$P2NMR#-$ZB?0/X^P"F(J
M,)"OPT!>X=E_3.VI-0-ML)0:OC*LG>TVM$+H;#9K2<\=6\#.MJA"J.^02SU0
M6&8QX+&9._2S5#<B?JVV:&L:&[H5'V;2.6&V:B>02C9S-U[!6P=:WVS1=@3=
M94=UE^<SL2]Y1A5 S9R]U4ZP=V*$=7+ 8@"=9@8?FS]K3%$8^>R@2?TD^/K!
M/F#AIK*V"KN\G2BIC;7%9"2O17/R!0TSM'TI=A?E)P@:19OQ/">?BIS9A50R
M-,)]&I>M7F-*3 =]G3IJ4]J/S^EV#&;@M/'G$3D-B"DT,.&B@]2W?^D=PM(]
MD20YD53CT\]%%2\T52>"4_L^,%0IHPEL9:PK\5Z R2L=)C_]#']&WJ9^)RC!
M_B(BP[;3[Q]1ZA$:SW5 4;9-@PVR:MZ)G% RG].-Q=7FIQWR0J5@R.>3T9DI
M>Q(NF=D^4,JG7":UI+Z8.^Z[V]Z]O1RU&#$_9X%9.A.!*3ZC?-3*/S\0"JQS
M9Q=2]?)D,V:S86G.Y\'?O+?O?_KF\7A6 980B3PY:Z9-;/WF5+WF&WXWZ-^!
M2*28+EPJ$JP6KV5)7+^ Y<0G2V-Y/*Q?D8C0"\\!VM2_(F 6OA=P6+AHL!^2
M6[RD?UMZEZ]&6[_B@%&(A7LP+6OA>^T1\AG!CF$*%JR$SK)@QA8G0Q;707A4
MI='=C^VP88D;4T\31$+LKG#_S930QDMW4#$\WD2[UV(7ZJ&7T03+-,*JS>5_
MENZC!0:!>%/PC:E_7L4TALT&"%-R@#%%E:\IYT#:&W]3IB)A<*I$G_[@.%4
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M,C R,S R,34N:'1M4$L! A0#%     @ T3M05F$3=?$. P  H0D  !$
M         ( !5S0  &EN>GDM,C R,S R,34N>'-D4$L! A0#%     @ T3M0
M5N]AF@S=!0  3S8  !4              ( !E#<  &EN>GDM,C R,S R,35?
M;&%B+GAM;%!+ 0(4 Q0    ( -$[4%9F$<Q;KP0  /,G   5
M  "  :0]  !I;GIY+3(P,C,P,C$U7W!R92YX;6Q02P$"% ,4    " #1.U!6
MM:,WS5$K  !7'P( #P              @ &&0@  :6YZ>2UE>#DY7S$N:'1M
64$L%!@     %  4 00$   1N      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
